Evidence map›Paper›PMID 33229802›Full record

ArticleInternal medicine (Tokyo, Japan)2021

Interstitial Pneumonia Secondary to Hermansky-Pudlak Syndrome Type 4 Treated with Different Antifibrotic Agents.

Junko Itano, Yasushi Tanimoto, Goro Kimura, Noboru Hamada, Hisaaki Tanaka, Shinsuke Ninomiya, Kenjiro Kosaki, Nobuaki Miyahara, Yoshinobu Maeda, Katsuyuki Kiura

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Junko ItanoDepartment of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center, Japan.
Yasushi TanimotoDepartment of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center, Japan.
Goro KimuraDepartment of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center, Japan.
Noboru HamadaDepartment of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center, Japan.
Hisaaki TanakaDepartment of Allergy and Respiratory Medicine, National Hospital Organization Minami-Okayama Medical Center, Japan.
Shinsuke NinomiyaDepartment of Clinical Genetics, Kurashiki Central Hospital, Japan.
Kenjiro KosakiCenter for Medical Genetics, Keio University School of Medicine, Japan.
Nobuaki MiyaharaDepartment of Medical Technology, Okayama University Graduate School of Health Sciences, Dentistry and Pharmaceutical Sciences, Japan.
Yoshinobu MaedaDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan.
Katsuyuki KiuraDepartment of Allergy and Respiratory Medicine, Okayama University Hospital, Japan.
Okayama Medical Center · JPOkayama University · JPKeio University · JPKurashiki Central Hospital · JPNational Hospital Organization · JPOkayama University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hermansky-Pudlak syndrome (HPS) is an autosomal recessive hereditary disease that may be complicated by progressive and potentially fatal interstitial pneumonia. We herein report a 64-year-old woman with interstitial pneumonia associated with HPS type 4 whom we treated with nintedanib after pirfenidone proved ineffective. To our knowledge, there have been no previous reports of nintedanib being used to treat a patient with HPS type 4. There is a need for clinical trials of antifibrotic agents, including nintedanib, pirfenidone, and new therapeutic agents with different mechanisms of action in these patients.

Indexed as

Hermanski-Pudlak SyndromeLung Diseases, InterstitialPulmonary FibrosisFemaleHumansMiddle Agedantifibrotic agentsHermansky-Pudlak syndrome type 4idiopathic pulmonary fibrosisinterstitial pneumonianintedanibpirfenidone

Identifiers

PMID33229802
PMCPMC7990633
OpenAlexW3110082245

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.